Rutger H.T. Koornstra

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.8K citations · Full text

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 421 citations · Full text

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2020 · 268 citations · Full text

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Gerty Schreibelt, Kalijn F. Bol, Harm Westdorp et al. · Clinical Cancer Research · 2015 · 231 citations